Agios Pharmaceuticals, Inc. (AGIO) Financial Analysis & Valuation | Quarter Chart
Agios Pharmaceuticals, Inc. (AGIO)
AGIOPrice: $42.79
Fair Value: 🔒
🔒score
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzym... more
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development o... more
Description
Shares
| Market Cap | $2.54B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Brian Goff |
| IPO Date | 2013-07-24 | CAGR | 0.07% |
| Employees | 486 | Website | www.agios.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
AGIO chart loading...
Fundamentals
Technicals
| Enterprise Value | $2.77B | P/E Ratio | -5.9 |
| Forward P/E | -9.33 | PEG Ratio | — |
| P/S Ratio | 670.65 | P/B Ratio | 39.15 |
| P/CF Ratio | -115.06 | P/FCF Ratio | -115.06 |
| EPS | $-7.25 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 78.34% | Gross Margin | 0.82% |
| Operating Margin | -7.2% | Profit Margin | -6.4% |
| ROE | -0.34% | ROA | -0.36% |
| ROCE | -0.42% | Current Ratio | 14.19 |
| Quick Ratio | 13.59 | Cash Ratio | 1.93 |
| Debt/Equity | 0.03 | Interest Coverage | — |
| Altman Z Score | 18.76 | Piotroski Score | 3 |